DOI: 10.1111/jdv.17247 JEADV

## CORRIGENDUM

The institutional affiliation of Flavio A. Cadegiani was incorrectly listed as 'Federal University of São Paulo' in the following articles: '5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia'; 'Clinical symptoms of hyperandrogenic women diagnosed with COVID-19'2; 'Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men'3; 'Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients'.<sup>4</sup>

This should be corrected as follows:

## Flavio A. Cadegiani<sup>1,2</sup>

<sup>1</sup>Corpometria Institute, Brasilia, DF, Brazil.

<sup>2</sup>Applied Biology Inc, Irvine, CA, USA.

## References

- 1 McCoy J, Cadegiani FA, Wambier CG et al. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol 2021; 35: e243–e307.
- 2 Cadegiani FA, Lim RK, Goren A et al. Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol 2021; 35: e97–e163.
- 3 Goren A, Wambier CG, Herrera S *et al.* Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. *J Eur Acad Dermatol Venereol* 2021; **35**: e1–e96.
- 4 McCoy J, Wambier CG, Herrera S et al. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021; 35: e1–e96.